Skip to Content

EADV24: Breakthrough in Early Melanoma Detection Using Tumour-Specific Antibodies

New research unveiled at the EADV Congress 2024 reveals a promising advancement in melanoma detection. This novel method utilises tumour-specific antibodies to identify early-stage melanoma, potentially revolutionising diagnosis and improving patient outcomes by detecting the disease at its most treatable stages.

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top